Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Saniona Launches New Video Series to Highlight the Impact of Prader-Willi Syndrome and .
Saniona ABMay 10, 2021 GMT
PRESS RELEASE
May 10, 2021
Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced its “Saniona’s Community Voices” video series, which will feature the voices of people living with rare diseases, their caregivers and their medical professionals. The series will launch during the month of May, which is both Prader-Willi syndrome (PWS) and Brain Tumor Awareness Month and will begin by spotlighting the impact of these conditions on patients and their families.
Saniona AB: Saniona publishes its Annual Report for 2020
that the English version of the Annual
R
,
Trista Morrison, Chief Communications Officer, Saniona. Office: + 1
This information was submitted for publication, through the agency of the contact persons set out above, at
17.55
About Saniona
Saniona is a biopharmaceutical company focused on discovering, developing, and delivering innovative treatments for rare disease patients around the world. The company s lead product candidate, Tesomet, is in mid-stage clinical trials for hypothalamic obesity and Prader-Willi syndrome, severe rare disorders characterized by uncontrollable hunger and intractable weight gain. Saniona s robust drug discovery engine has generated a library now consisting of more than 20,000 proprietary modulators of ion channels, a significantly untapped drug class that is scientifically validated. Lead candidate SAN711 is entering Phase 1 for rare neuropathic disorders, with SAN903 for rare inflammatory
Notice of Saniona AB annual shareholders meeting
April 23, 2021
The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.
The shareholders in Saniona AB, Reg. No. 556962-5345, are hereby invited to the annual shareholders meeting (
Sw
.
In light of the ongoing Covid-19 pandemic and in order to reduce the risk of infection spreading, the board of directors has resolved that the annual shareholders meeting will be held only by advance voting (postal vote) in accordance with temporary legislation. This means that the annual shareholders meeting will be conducted without the physical presence of shareholders, proxies or external parties and that shareholders exercise of voting rights at the annual shareholders meeting can only take place by advance shareholders voting in the order prescribed below. Information on the resolutions passed by the annual shareholders meeting wi
manufacturing
. Saniona anticipates that addressing these requests will delay the start of the Phase 2b trials of Tesomet for Prader-Willi syndrome (PWS) and hypothalamic obesity (HO) into the second half of 2021.
Tesomet is an investigational fixed-dose combination of tesofensine (a triple monoamine reuptake inhibitor) and metoprolol (a beta-1 selective blocker). In preparation for Phase 2b through Phase 3 clinical trials and eventual commercialization, Saniona has taken multiple steps to optimize the manufacturing of Tesomet, including transitioning from tablets to capsules. The company chose to utilize a capsule form because some individuals with PWS and HO have a tendency to chew tablets, which would disrupt the performance of the fixed-dose combination. The Tesomet capsules contain the two active ingredients as microspheres, which are expected to minimize the impact of chewing or biting. Additionally, capsules are generally easier to swallow than tablets and facilitate the dev